Literature DB >> 22748656

Nanotechnology applications for glioblastoma.

Edjah K Nduom1, Alexandros Bouras, Milota Kaluzova, Costas G Hadjipanayis.   

Abstract

Glioblastoma remains one of the most difficult cancers to treat and represents the most common primary malignancy of the brain. Although conventional treatments have found modest success in reducing the initial tumor burden, infiltrating cancer cells beyond the main mass are responsible for tumor recurrence and ultimate patient demise. Targeting residual infiltrating cancer cells requires the development of new treatment strategies. The emerging field of cancer nanotechnology holds promise in the use of multifunctional nanoparticles for imaging and targeted therapy of glioblastoma. This article examines the current state of nanotechnology in the treatment of glioblastoma and directions of further study.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748656      PMCID: PMC3473084          DOI: 10.1016/j.nec.2012.04.006

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  122 in total

1.  Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery.

Authors:  Changyou Zhan; Qinggang Meng; Qinghua Li; Linglin Feng; Jianhua Zhu; Weiyue Lu
Journal:  Chem Asian J       Date:  2011-11-09

2.  Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles.

Authors:  Hyon Bin Na; Jung Hee Lee; Kwangjin An; Yong Il Park; Mihyun Park; In Su Lee; Do-Hyun Nam; Sung Tae Kim; Seung-Hoon Kim; Sang-Wook Kim; Keun-Ho Lim; Ki-Soo Kim; Sun-Ok Kim; Taeghwan Hyeon
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

Review 3.  Magnetic nanoparticles in MR imaging and drug delivery.

Authors:  Conroy Sun; Jerry S H Lee; Miqin Zhang
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

4.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides.

Authors:  R Suto; P K Srivastava
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

5.  Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules.

Authors:  Claire Vanpouille-Box; Franck Lacoeuille; Camille Belloche; Nicolas Lepareur; Laurent Lemaire; Jean-Jacques LeJeune; Jean-Pierre Benoît; Philippe Menei; Olivier F Couturier; Emmanuel Garcion; François Hindré
Journal:  Biomaterials       Date:  2011-06-25       Impact factor: 12.479

6.  Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Authors:  John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

Review 7.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

8.  Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent.

Authors:  Philippe Bourrinet; Howard H Bengele; Bruno Bonnemain; Anne Dencausse; Jean-Marc Idee; Paula M Jacobs; Jerome M Lewis
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells.

Authors:  Angeles Villanueva; Magdalena Cañete; Alejandro G Roca; Macarena Calero; Sabino Veintemillas-Verdaguer; Carlos J Serna; María del Puerto Morales; Rodolfo Miranda
Journal:  Nanotechnology       Date:  2009-02-24       Impact factor: 3.874

10.  Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters.

Authors:  Svetlana Gelperina; Olga Maksimenko; Alexander Khalansky; Lyudmila Vanchugova; Elena Shipulo; Kenul Abbasova; Rustam Berdiev; Stefanie Wohlfart; Nina Chepurnova; Jörg Kreuter
Journal:  Eur J Pharm Biopharm       Date:  2009-09-13       Impact factor: 5.571

View more
  11 in total

Review 1.  Current progress for the use of miRNAs in glioblastoma treatment.

Authors:  Amanda Tivnan; Kerrie Leanne McDonald
Journal:  Mol Neurobiol       Date:  2013-04-28       Impact factor: 5.590

Review 2.  Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.

Authors:  Nolan Ung; Isaac Yang
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

Review 3.  Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.

Authors:  William T Phillips; Ande Bao; Andrew J Brenner; Beth A Goins
Journal:  Adv Drug Deliv Rev       Date:  2014-07-09       Impact factor: 15.470

4.  Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro.

Authors:  Huai-Lu Chen; Fei-Ting Hsu; Yu-Chieh Jill Kao; Hua-Shan Liu; Wan-Zhen Huang; Chia-Feng Lu; Ping-Huei Tsai; Ahmed Atef Ahmed Ali; Gilbert Aaron Lee; Ray-Jade Chen; Cheng-Yu Chen
Journal:  J Nanobiotechnology       Date:  2017-11-22       Impact factor: 10.435

Review 5.  Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma.

Authors:  Amy Lee Bredlau; Suraj Dixit; Chao Chen; Ann-Marie Broome
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas.

Authors:  Chun-I Sze; Wan-Pei Su; Ming-Fu Chiang; Chen-Yu Lu; Yu-An Chen; Nan-Shan Chang
Journal:  Front Oncol       Date:  2013-03-19       Impact factor: 6.244

7.  Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells.

Authors:  Maryam Tahmasebi Mirgani; Benedetta Isacchi; Majid Sadeghizadeh; Fabio Marra; Anna Rita Bilia; Seyed Javad Mowla; Farhood Najafi; Esmael Babaei
Journal:  Int J Nanomedicine       Date:  2014-01-13

Review 8.  Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy.

Authors:  Elif Ozdemir-Kaynak; Amina A Qutub; Ozlem Yesil-Celiktas
Journal:  Front Physiol       Date:  2018-03-19       Impact factor: 4.566

9.  Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.

Authors:  Laura Pinton; Sara Magri; Elena Masetto; Marina Vettore; Ilaria Schibuola; Vincenzo Ingangi; Ilaria Marigo; Kevin Matha; Jean-Pierre Benoit; Alessandro Della Puppa; Vincenzo Bronte; Giovanna Lollo; Susanna Mandruzzato
Journal:  J Nanobiotechnology       Date:  2020-02-17       Impact factor: 10.435

10.  Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide.

Authors:  Gilbert Aaron Lee; Wan-Li Lin; Duen-Pang Kuo; Yi-Tien Li; Yu-Wei Chang; Yung-Chieh Chen; Shiu-Wen Huang; Justin Bo-Kai Hsu; Cheng-Yu Chen
Journal:  Int J Nanomedicine       Date:  2021-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.